Covenant Partners’s GSK GSK Stock Holding History

Covenant Partners’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,414	Closed	-$462K	–	49
2025 Q4	$462K	Hold	9,414	–	–	0.14%	75
2025 Q3	$406K	Hold	9,414	–	–	0.12%	85
2025 Q2	$361K	Hold	9,414	–	–	0.11%	93
2025 Q1	$365K	Hold	9,414	–	–	0.12%	90
2024 Q4	$318K	Sell	9,414 -1	-0%	-$36	0.1%	108
2024 Q3	$385K	Sell	9,415 -1,180	-11%	-$48.3K	0.11%	108
2024 Q2	$408K	Buy	10,595 +1,181	+13%	+$49.7K	0.12%	110
2024 Q1	$404K	Hold	9,414	–	–	0.12%	116
2023 Q4	$349K	Sell	9,414 -985	-9%	-$35.4K	0.11%	128
2023 Q3	$377K	Buy	+10,399	New	+$369K	0.14%	118
2022 Q3	–	Sell	-8,664	Closed	-$471K	–	175
2022 Q2	$471K	Hold	8,664	–	–	0.22%	89
2022 Q1	$472K	Buy	+8,664	New	+$471K	0.19%	103

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Covenant Partners's GSK Position: Q1 2026 in Review

Covenant Partners sold out of GSK (GSK) in Q1 2026, closing a stake of 9,414 shares — an estimated $462K sold.

Covenant Partners first reported a position in GSK in Q1 2022 and held it in 12 quarters. The position peaked at $472K in Q1 2022. 1,031 funds tracked by Wall St. Rank hold GSK as of Q1 2026.

Covenant Partners reported no remaining GSK position as of Q1 2026 after selling out during the quarter.
Covenant Partners sold 9,414 GSK shares in Q1 2026, an estimated $462K.
Covenant Partners first reported a position in GSK in Q1 2022 and held it in 12 quarters.
Covenant Partners's GSK position peaked at $472K in Q1 2022.
1,031 funds tracked by Wall St. Rank held GSK as of Q1 2026.

Based on Covenant Partners's 13F filing for Q1 2026.